García-Frade RLF, Cuellar- Gamboa L

Language: Spanish
References: 23
Page: 103-114
PDF size: 703.50 Kb.

ABSTRACT

The thrombus as a phenomenon of vascular disease should always be a differential diagnosis in addressing study of patients whatever the affected organ, which is a diagnostic challenge for the clinician. In this article it is summarized the main clinical manifestations and how to establish the diagnosis in the various places where the thrombus is located. Some practical steps in the study and treatment of patients are suggested, as well as how to choose today among different antithrombotic drugs commercially available.

REFERENCES

1. García-Frade LF. Sistema normal de la coagulación. En: Tratado de trombosis. García-Frade LF. México: Alfil, 2015.

2. Sarmina JS. Oftalmología y trombosis. En: Tratado de trombosis. García-Frade LF. México: Alfil, 2015.

3. García-Frade LF. Enfermedad vascular renal. En: Tratado de trombosis. García-Frade LF. México: Alfil, 2015.

4. Alcazar J, Rodicio J. Ischemic nephropathy: clinical characteristics and treatment. Am J Kidney Dis 2000;36:883- 893.

5. Vargas S, Mundo LF. Trombosis mesentérica. En: Tratado de trombosis. García-Frade LF. México: Editorial Alfil, 2015.

6. Connolly SJ, Ezekowitz MD, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.

7. Patel MR, Mahaffey KW, Garg J. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.

8. Connolly S, Eikelboom J, Joyner C. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817.

9. García-Frade LF, Solís E. Los nuevos anticoagulantes orales: una realidad. Med Int Mex 2013;29:171-178.

10. Tendera M, Syzdól M, Parma Z. ARISTOTLE RE-LYs on the ROCKET. What’s new in stroke prevention in patients with atrial fibrillation? Cardiol J 2012;19:4-10.

11. Guyatt G, Akl E, Crowther M, et al. Antithrombotic therapy and prevention of thrombosis, 9a ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141;7-41.

12. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation.

13. García-Frade LF. Embarazo y trombosis. En: Tratado de trombosis. García-Frade LF. México: Alfil, 2015.

14. García- Frade LF. Anticonceptivos orales, terapia hormonal sustitutiva y trombosis. En: Tratado de trombosis. García- Frade LF. México: Editorial Alfil, 2015.

15. Cuevas C, Pérez I. Trombosis venosa cerebral. En: Tratado de trombosis. García-Frade LF. México: Alfil, 2015.

16. De la Garza, García-Frade LF, Lomelín J. Trombosis en el paciente oncológico. En: Tratado de trombosis. García- Frade LF. México: Alfil, 2015.

17. Gallegos M. Tromboembolia pulmonar. En: Tratado de trombosis. García-Frade LF. México: Alfil, 2015.

18. García-Frade LF, Solís E. Trombosis venosa yugular externa. Med Int Mex 2014;30:88-91.

19. García-Frade LF, Mas AP. Trombosis venosa yugular interna espontánea. Med Int Mex 2005;21:477-480.

20. García-Frade LF: Enfermedad vascular. Un enfoque clínico. México: Alfil, 2015.

21. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-2352.

22. The EINSTEIN Investigators. Oral rivaroxabán for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-2510.

23. van Ryn J, Litzenburger T, Schurer J. Reversal of anticoagulant activity of dabigatran and dabigatran-induced bleeding in rats by a specific antidote (antibody fragment). Circulation 2012;126:9928.